Table 1.
Role of miR-30c in human cancers
| Cancer | Expression | Target | Function& Biomarker | Reference |
|---|---|---|---|---|
| Myc-induced B cell lymphoma | Unknown | Tumor-suppressing | 17 | |
| Breast | Decreased | KRAS | Inhibits metastasis | 48 |
| VIM/TWF1 | Inhibits invasion;a potential sensitive chemotherapy biomarker | 38 | ||
| HER/RACI | A potential tamoxifengood prognosis biomarker | 49 | ||
| Colon | Decreased | ADAM19 | Inhibit cells proliferation , metastasis and invasion | 33 |
| Bladder | Decreased | Unknown | Tumor-suppressing | 50 |
| Medulloblastoma | Decreased | Unknown | Tumor-suppressing | 34 |
| Lung | Decreased | Rab18 | Inhibited proliferation | 51 |
| Vimentin ,Fibronectin, and MTDH , HMGA2 | Inhibited metastasis | 52 | ||
| Tyrosine kinases | A potential tyrosine kinase inhibitor sensitivity biomarker | 53 | ||
| Endometrium | Decreased | MTA1 | Tumor-suppressing, inhibited clles growth, migration and invasion, | 39,40 |
| Prostate | Decreased | CCND2 | Tumor-suppressing and a potential Sulfuretin-sensitive biomarker | 41 |
| Possibly kRAS/MAPK | Inhibited cell growth, invasion and metastasis.A potential prognosis biomarker | |||
| Liver | Decreased | HMBOX1 | IFN-alfal and NK cell cytotoxicity increase | 45 |
| IER2 | Inhibited cell motility | 44 | ||
| Ovarian | Decreased | BCL9 | Inhibited cell proliferation | 46 |
| large cell lymphoma (C-ALCL) | Increased | Unknown | A different contribution to the pathogenesis of these lymphomas. | 54 |
| multiple myeloma | Decreased | BCL9 | Influence tumor cell proliferation, apoptosis, transfer, drug resistance and tumor stem cell formation | 37 |